LXRX
Lexicon Pharmaceuticals
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: LXRX
- PE Ratio
The current price-to-earnings ratio of LXRX can't be determined, as the TTM EPS of -$0.07 is negative. The most recent PE ratio recorded for Lexicon Pharmaceuticals was 9.98 in June 2021.
LXRX PE ratio history
Over the last seven years, the average PE ratio of Lexicon Pharmaceuticals has been 4.63. In the past seven years, LXRX's PE ratio was at its highest in the Jun 2021 quarter at 9.98, with a price of $4.59 and an EPS of $0.46. The Sep 2019 quarter recorded the bottom point at 1.95, with a price of $3.01 and an EPS of $1.54.
Lexicon Pharmaceuticals PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | N/A | N/A | $1.15 | -$0.14 |
| 2024 | N/A | N/A | $0.74 | -$0.63 |
| 2023 | N/A | N/A | $1.53 | -$0.8 |
| 2022 | N/A | N/A | $1.91 | -$0.62 |
| 2021 | N/A | N/A | $3.94 | -$0.6 |
| 2020 | N/A | N/A | $3.42 | -$0.53 |
| 2019 | 3.37 | N/A | $4.15 | $1.23 |
| 2018 | N/A | N/A | $6.64 | -$1.14 |
| 2017 | N/A | N/A | $9.88 | -$1.17 |
| 2016 | N/A | N/A | $13.83 | -$1.27 |
| 2015 | N/A | N/A | $13.31 | -$0.05 |
| 2014 | N/A | N/A | $6.37 | -$1.31 |
| 2013 | N/A | N/A | $12.59 | -$1.42 |
| 2012 | N/A | N/A | $15.47 | -$1.61 |
| 2011 | N/A | N/A | $9.03 | -$2.38 |
Lexicon Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | N/A | N/A | $1.56 | -$0.07 |
| Dec 2025 | N/A | N/A | $1.15 | -$0.14 |
| Sep 2025 | N/A | N/A | $1.35 | -$0.19 |
| Jun 2025 | N/A | N/A | $0.95 | -$0.33 |
| Mar 2025 | N/A | N/A | $0.46 | -$0.51 |
| Dec 2024 | N/A | N/A | $0.74 | -$0.63 |
| Sep 2024 | N/A | N/A | $1.57 | -$0.75 |
| Jun 2024 | N/A | N/A | $1.68 | -$0.78 |
| Mar 2024 | N/A | N/A | $2.4 | -$0.83 |
| Dec 2023 | N/A | N/A | $1.53 | -$0.8 |
| Sep 2023 | N/A | N/A | $1.09 | -$0.77 |
| Jun 2023 | N/A | N/A | $2.29 | -$0.69 |
| Mar 2023 | N/A | N/A | $2.43 | -$0.63 |
| Dec 2022 | N/A | N/A | $1.91 | -$0.62 |
| Sep 2022 | N/A | N/A | $2.4 | -$0.62 |
LXRX Price vs fair value
LXRX average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
PE comparison
LXRX PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| REGN Regeneron Pharmaceuticals Inc | 14.54 | $64.89B |
| TMO Thermo Fisher Scientific Inc | 26.01 | $176.13B |
| LGND Ligand Pharmaceuticals Inc | 29.67 | $4.7B |
| ILMN Illumina Inc | 30.97 | $25.86B |
| BMRN Biomarin Pharmaceutical Inc | 39.04 | $10.56B |
| RARE Ultragenyx Pharmaceutical Inc | N/A | $2.21B |
| ESPR Esperion Therapeutics Inc | N/A | $808.34M |
| LXRX Lexicon Pharmaceuticals Inc | N/A | $821.76M |
Frequently asked questions
What is Lexicon Pharmaceuticals's PE ratio?
The current price to earnings ratio of LXRX can't be calculated, as its EPS of -$0.07 is negative.
What is the highest PE ratio for LXRX?
The highest quarterly PE ratio in the last seven years has been 9.98 and it was in the Jun 2021 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.